Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orally active fusion inhibitor of respiratory syncytial virus.

Antimicrobial agents and chemotherapy - 1 Feb 2004

Cianci Christopher, Yu Kuo-Long, Combrink Keith, Sin Ny, Pearce Bradley, Wang Alan, Civiello Rita, Voss Stacey, Luo Guangxiang, Kadow Kathy, Genovesi Eugene V, Venables Brian, Gulgeze Hatice, Trehan Ashok, James Jennifer, Lamb Lucinda, Medina Ivette, Roach Julia, Yang Zheng, Zadjura Lisa, Colonno Richard, Clark Junius, Meanwell Nicholas, Krystal Mark

Abstract excerpt

BMS-433771 was found to be a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro. It exhibited excellent potency against multiple laboratory and clinical isolates of both group A and B viruses, with an average 50% effective concentration of 20 nM. Mechanism-of-action studies demonstrated that BMS-433771 inhibits the fusion of lipid membranes during both the early virus entry stage and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Giant Cells

Share to Respiratory Syncytial Virus Infections

Share to Respiratory Syncytial Viruses

Share to Viral Fusion Proteins

Share to Viral Plaque Assay

Share to Viral Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 14742189
DOI: 10.1128/AAC.48.2.413-422.2004
PMCID: PMC321540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orally active fusion inhibitor of respiratory syncytial virus.PMID 14742189Read ↗

Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitorSemantic proximity Read ↗

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate modelSemantic proximity Read ↗

Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.Semantic proximity Read ↗

Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.Semantic proximity Read ↗

Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.Semantic proximity Read ↗

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

RSV604, a novel inhibitor of respiratory syncytial virus replication.Semantic proximity Read ↗

Discovery of a Novel Respiratory Syncytial Virus Replication InhibitorSemantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.Semantic proximity Read ↗

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.